San Francisco, CA-August 22, 2006 - AlloPort, a real-time, neutral B2B procurement platform purpose-built for AATB-accredited tissue banks and hospital/ASC operating room procurement teams, today announced its planned public launch on September 1, 2026, followed by its industry debut at the American Association of Tissue Banks (AATB) Annual Conference in San Francisco on October 4.
AlloPort Launches on September 1 Leveling the Playing Field for Accredited Tissue Banks and Expanding Hospital Access to Allografts
2 min read Premium comments
#allograftsAlloPortChris FureJames ForsellNikki Couloumbispublic launch
AlloPort was created for the tissue banking industry by tissue banking people. Its leadership and advisory team includes Dr. James Forsell, former Chairman of the American Association of Tissue Banks; Nikki Couloumbis, Founder of Allografts.com; and a veteran team of operators with collectively more than 100 years of healthcare experience assembled by serial entrepreneur Chris Fure.
“AlloPort exists because the tissue banking market needs a credible, industry-aligned procurement platform that expands access without disrupting the trusted role of accredited tissue banks,” said Fure, AlloPort Co-Founder & CEO. “Surgeons need better access to best-fit allografts, procurement managers need faster discovery, and tissue banks deserve a direct, efficient path to operating rooms without surrendering margin to unnecessary intermediaries.”
A Neutral Exchange — Not a Distributor
AlloPort lists inventory and processes orders, but does not hold, store, relabel, or ship allografts. Accredited tissue banks maintain custody, quality control, pricing authority, and fulfillment responsibility. AlloPort routes orders directly to the originating tissue bank for acceptance and fulfillment, while supporting accreditation visibility, state-license gating, lot/UDI traceability, document access, recall readiness, and audit-trail confirmation.
“AlloPort reflects best practices the tissue banking community has advanced for years — license eligibility, traceability, recall readiness, and procurement transparency — now made practical through a single-source procurement solution,” said Dr. Forsell, AlloPort Co-Founder & CBO (brand).
This sentiment was expanded by Couloumbis, AlloPort Co-Founder & CSO (sales): “It preserves the role of accredited banks while helping procurement managers find the right graft faster.”
Built to Work With the Systems Tissue Banks Already Use
AlloPort’s platform centralizes lot-level allograft listings into a single searchable catalog while allowing each tissue bank to continue using its existing inventory management system. The company’s fragmented data aggregation and normalization technology was pioneered by AlloPort Co-Founder & CTO Jim Chu (founder of EMBD Finance, formerly with Cisco Systems).
“AlloPort’s technology was designed to remove friction, not add it,” said Chu. “A tissue bank should not have to overhaul its inventory system to participate in a modern procurement network. AlloPort meets banks where they are, normalizes fragmented data, makes available allografts discoverable in real time, and offers side-by-side comparison for the procurement teams who need them.”
Moreover, surgeons benefit from expanded access to graft options that may better align with procedural requirements, patient anatomy, and scheduling demands. “This would definitely be a helpful tool,” remarked Dr Philip Omohundro, of the Centers for Advanced Orthopedics in Silver Spring, MD.
Media Contact
Mark Russo, VP Marketing
AlloPort LLC
mrusso@alloport.com +1 (415) 806-4625
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
AlloPort is launching a neutral B2B procurement platform on September 1, 2026, aiming to level the playing field for AATB-accredited tissue banks and expand hospital/ASC access to allografts. This strategy seeks to improve market efficiency by providing direct access for tissue banks to operating rooms, bypassing intermediaries and preserving their margins. The platform centralizes listings while allowing banks to maintain existing inventory systems.
- The company's competitive strategy is to act as a neutral exchange, not a distributor, ensuring tissue banks retain custody, quality control, and pricing authority.
- Adoption is facilitated by technology that integrates with existing tissue bank inventory systems, minimizing friction and lowering barriers to participation.
PhD Lens: Clinical and outcomes impact
AlloPort is a B2B procurement platform designed to enhance access to allografts for surgical teams by centralizing lot-level listings. It supports critical safety and quality control features, including accreditation visibility, state-license gating, lot/UDI traceability, and recall readiness. This system aims to ensure procurement transparency and adherence to industry best practices, making allografts discoverable in real time for better surgical alignment.
- The platform's mechanism involves aggregating and normalizing fragmented data from existing tissue bank inventory systems into a single searchable catalog.
- Safety and quality are maintained as accredited tissue banks retain custody and quality control, while AlloPort supports essential traceability and recall readiness functions.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.